BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) antibodies while eking out its cash to cover a slew of clinical readouts over the next couple of years.
https://www.fiercebiotech.com/biotech/bioatla-lays-30-staff-hunts-partners-adc-and-cancer-antibody